AbCellera Biologics Inc.
$3.91
▲
0.28%
2026-04-21 05:01:00
www.abcellera.com
NMS: ABCL
Explore AbCellera Biologics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.22 B
Current Price
$3.91
52W High / Low
$6.51 / $1.94
Stock P/E
—
Book Value
$3.22
Dividend Yield
—
ROCE
-15.72%
ROE
-14.47%
Face Value
—
EPS
$-0.49
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
562
Beta
0.85
Debt / Equity
14.81
Current Ratio
11.32
Quick Ratio
11.23
Forward P/E
-4.6
Price / Sales
14.28
Enterprise Value
$682.58 M
EV / EBITDA
-3.5
EV / Revenue
9.09
Rating
Strong Buy
Target Price
$9.17
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Xeris Biopharma Holdings, Inc. | $6.25 | 1,885.02 | $1.04 B | — | 9.09% | -6.96% | $10.08 / $3.95 | $0.08 |
| 2. | 4D Molecular Therapeutics, Inc. | $10.07 | — | $535.53 M | — | -30.52% | -27.57% | $12.34 / $2.88 | $8.78 |
| 3. | Prime Medicine, Inc. | $3.89 | — | $687.9 M | — | -68.25% | -1.47% | $6.94 / $1.11 | $0.68 |
| 4. | Immix Biopharma, Inc. | $10.09 | — | $548.68 M | — | -31.62% | -55% | $11.61 / $1.57 | $1.77 |
| 5. | NeuroSense Therapeutics Ltd. | $0.71 | — | $25.1 M | — | -383.35% | -21.75% | $2.6 / $0.63 | $-0.05 |
| 6. | Bio Green Med Solution, Inc. | $1.19 | — | $6.54 M | 0.93% | 552.16% | -1.28% | $100.8 / $0.73 | $1.27 |
| 7. | Oculis Holding AG | $28.61 | — | $1.64 B | — | -41% | -73.45% | $30.68 / $16 | $4.24 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 44.85 M | 8.96 M | 17.08 M | 4.24 M | 5.05 M | — |
| Operating Profit | -25.27 M | -73.55 M | -45.89 M | -58.51 M | -69.21 M | — |
| Net Profit | -8.95 M | -57.12 M | -34.73 M | -45.62 M | -34.21 M | — |
| EPS in Rs | -0.03 | -0.19 | -0.11 | -0.15 | -0.11 | -0.17 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 75.13 M | 28.83 M | 38.02 M | 485.42 M |
| Operating Profit | -203.21 M | -301.15 M | -223.05 M | 227.06 M |
| Net Profit | -146.41 M | -162.86 M | -146.4 M | 158.52 M |
| EPS in Rs | -0.48 | -0.54 | -0.48 | 0.52 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.36 B | 1.36 B | 1.49 B | 1.54 B |
| Total Liabilities | 390.05 M | 304.47 M | 335.78 M | 307.63 M |
| Equity | 966.9 M | 1.06 B | 1.15 B | 1.23 B |
| Current Assets | 728.23 M | 751.37 M | 871.99 M | 1.03 B |
| Current Liabilities | 64.31 M | 76.61 M | 119.01 M | 118.32 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -131.29 M | -108.56 M | -43.88 M | 277.36 M |
| Investing CF | 87.75 M | 121.41 M | -221.11 M | -352.62 M |
| Financing CF | 14.08 M | 12.77 M | 10.36 M | -1.63 M |
| Free CF | -174.07 M | -186.95 M | -120.82 M | 204.7 M |
| Capex | -42.77 M | -78.4 M | -76.95 M | -72.66 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -24.17% | -92.17% | — | — |
| Earnings Growth % | -11.24% | -192.35% | — | — |
| Profit Margin % | -564.83% | -385% | 32.66% | — |
| Operating Margin % | -1044.45% | -586.59% | 46.78% | — |
| Gross Margin % | 100% | 100% | 86.31% | — |
| EBITDA Margin % | -708.04% | -505.35% | 53.6% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.